Janssen takes steps towards Doxil manufacturing transition


Janssen Pharmaceuticals (JNJ -0.7%) says it has "reached an initial agreement to lease some parts" of a Bedford, Ohio Ben Venue plant, a move which shows "steps are being taken to transition manufacturing" of Doxil, the popular cancer drug that has been in short supply since 2011 when Ben Venue halted production amid manufacturing problems.

Previously, the plan was to close the plant by the end of the year.

"There are multiple steps required to transition manufacturing and any plans are subject to health authority approvals," a JNJ spokesperson remarked.

For more, see: Doxil may remain scarce amid JNJ, Boehringer dispute

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs